FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person * WIKLER MATTHEW				2. Issuer Name and Ticker or Trading Symbol Matinas BioPharma Holdings, Inc. [MTNB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302				3. Date of Earliest Transaction (Month/Day/Year) 03/31/2021						Office	er (give title belo	ow)	Other (specify b	eelow)		
(Street) BEDMINSTER, NJ 07921				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City))	(State)	(Zip)	Table I - Non-Derivative Securities Acqu					ired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		f Coo	(Instr. 8)		4. Securities Acqui (A) or Disposed of (D) (Instr. 3, 4 and 5)		of	Beneficia	nt of Securities ally Owned Following Transaction(s) and 4)			7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code		V	Amoui		Price				(I) (Instr. 4)	(msu. 4)
Common	Stock		03/31/2021			A		7,560 (1)	A	\$ 0	251,863			D		
Reminder:	Report on a s	separate line fo	or each class of secur		Securi	ties Ac	equire	Perso conta the fo	ons whained i	no respo n this fo splays a	rm ar curre reficia	e not requently valid	OMB con	formation spond unle trol numbe	ss	1474 (9-02)
Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Execution Da Year) any			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. T Am Und Sec	Fitle and count of derlying purities str. 3 and	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivati Security Direct (or Indire	Beneficia Ownershi (Instr. 4)	
				Cod	e V	(A)	(D)	Date Exerc	cisable	Expiratio Date	n Titl	Amount or le Number of Shares				

Reporting Owners

	Relationships					
Reporting Owner Name / Address		10% Owner	Officer	Other		
WIKLER MATTHEW C/O MATINAS BIOPHARMA HOLDINGS, INC. 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER, NJ 07921	X					

Signatures

/s/ Keith A. Kucinski, attorney-in fact for Matthew Wikler	04/05/2021	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On March 31, 2021, the Reporting Person was issued 7,560 shares of common stock par value \$.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.